P446: Long-term Clinical Effectiveness And Stoma Outcome Of Fecal Diversion In Refractory Crohn’s ProctitisECCO'22Year: 2022
Authors: Benammi, S.(1);Perry, W.R.(1);Calini, G.(1);Abdalla, S.(1);Shawki, S.F.(1);Larson, D.W.(1);Mathis, K.L.(1);
(1)Mayo Clinic, Colon and Rectal Surgery, Rochester, United States;
P447: Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn’s diseaseECCO'22Year: 2022
Authors: Alsoud, D.(1);Sabino, J.(1,2);Ferrante, M.(1,2);vermeire, S.(1,2);Verstockt , B.(1,2);
(1)KU Leuven, Translational Research in Gastrointestinal Disorders- Department of Chronic Disease- Metabolism and Ageing, Leuven, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
P448: Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitisECCO'22Year: 2022
Authors: Kim, K.(1);Hong, H.S.(1);Oh, K.(1);Lee, J.Y.(1);Hong, S.W.(1);Park, J.H.(1);Hwang, S.W.(1,2);Yang, D.H.(1);Byeon, J.S.(1);Ye, B.D.(1,2);Myung, S.J.(1);Yang, S.K.(1,2);Park, S.H.(1,2);
(1)University of Ulsan College of Medicine- Asan Medical Center, Department of Gastroenterology, Seoul, Korea- Republic Of;(2)University of Ulsan College of Medicine- Asan Medical Center, Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of;
P449: Autologous fat graft injection for the treatment of perianal fistulas in Crohn’s disease: A systematic review and single-arm meta-analysisECCO'22Year: 2022
Authors: De Gregorio, M.(1,2);Tiang, T.(3);Lee, T.(1);Stellingwerf, M.E.(4);Basnayake, C.(1,2);Kamm, M.A.(1,2);Niewiadomski, O.(1,5);Schulberg, J.D.(1,2);Wright, E.K.(1,2);Connell, W.(1);Thompson, A.J.(1,2);D'Souza co-lead senior author, B.(3,6);Ding, N.S.(1,2);
(1)St Vincent's Hospital Melbourne, Department of Gastroenterology, Fitzroy, Australia;(2)University of Melbourne, Department of Medicine, Parkville, Australia;(3)St Vincent's Hospital Melbourne, Department of Colorectal Surgery, Fitzroy, Australia;(4)OLVG Hospital, Department of Surgery, Amsterdam, The Netherlands;(5)Monash University, Department of Medicine, Melbourne, Australia;(6)Northern Health, Department of Colorectal Surgery, Melbourne, Australia;
P450: Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel diseaseECCO'22Year: 2022
Authors: Livne- Margolin, M.(1);Ling, D.(1);Attia Konyo, S.(2);Haj, O.(1);Abitbol, C.M.(1);Ben-Horin, S.(1);Kopylov, U.(1);
(1)Tel-HaShomer Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;(2)Tel-HaShomer Sheba Medical Center, Internal Medicine E, Ramat Gan, Israel;
P451: Evaluating drug sustainability, efficacy and safety of biologic agents in elderly patients with Inflammatory Bowel Disease: a single center retrospective studyECCO'22Year: 2022
Authors: Golovics, P.(1);LeBlanc, J.F.(2);Drügg Hahn, G.(1);Wetwittayakhlang, P.(1);Qatomah, A.(1);Wang, A.(1);Boodaghians, L.(1);Liu, J.(3); Al Ali, M.(1);Wild, G.E.(1);Afif, W.(1);Bitton, A.(1);Lakatos, P.L.(1);Bessissow, T.(1);
(1)McGill University Health Centre, Division of Gastroenterology, Montreal, Canada;(2)Sacre-Coeur Hospital, Division of Gastroenterology, Montreal, Canada;(3)University of Montreal, Department of Gastroenterology, Montreal, Canada;
P452: Tofacitinib Effectiveness and Safety as Therapy for Ulcerative ColitisECCO'22Year: 2022
Authors: McNally, M.(1);Keating, E.(2);Gray, E.(1);McCormick, E.(1);Carroll, A.(3);Palmer, C.(4);Kennedy, U.(1);McKiernan, S.(1);MacCarthy, F.(1);Dunne, C.(1);Hartery, K.(1);Egan, L.(2);Slattery, E.(2);Ryan, B.(3);McNamara, D.(3);O'Connor, A.(3);Breslin, N.(3);O'Donnell, S.(3);Cullen, G.(4);Mulcahy, H.(4);Sheridan, J.(4);Doherty, G.(4);Kevans, D.(1);
(1)St. James's Hospital, Gastreonterology, Dublin, Ireland;(2)University Hospital Galway, Gastreonterology, Galway, Ireland;(3)Tallaght University Hospital, Gastroenterology, Dublin, Ireland;(4)St. Vincent's University Hospital, Gastroenterology, Dublin, Ireland;St. James's Hospital
P453: Underutilisation of novel and alternative oral iron preparations may incur unnecessary cost in iron deficiency anaemia treatment in inflammatory bowel diseaseECCO'22Year: 2022
Authors: Sharma, E.(1);Kotecha, J.(1);Akintimehin, A.(2);Ray, S.(1);Anderson, S.H.(1);Mawdsley, J.(1);Irving, P.M.(1);Samaan, M.A.(1);
(1)Guy’s and St Thomas’ NHS Foundation Trust, Inflammatory Bowel Disease centre, London, United Kingdom;(2)Guy’s and St Thomas’ NHS Foundation Trust, General medicine, London, United Kingdom;
P454: Evaluation of the nutritional care status in italian centers managing patients affected by inflammatory bowel diseaseECCO'22Year: 2022
Authors: Saibeni, S.(1);Bezzio , C.(1);Armuzzi, A.(2);Daperno, M.(3);Zanetti, M.(4);Vernero, M.(5); Giorgetti, G.M.(6);
(1)Rho Hospital- ASST Rhodense, Gastroenterology Unit-, Rho, Italy;(2)Fondazione Policlinico Universitario Gemelli IRCCS- Rome, CEMAD- IBD Unit- Internal Medicine and Gastroenterology Unit- Department of Medical and Surgical Sciences-, Roma, Italy;(3)Mauriziano Hospital- Turin, Gastroenterology Unit-, Turin, Italy;(4)Univeristà di Trieste, Dipartimento di Scienze Mediche e Chirurgiche-, Trieste, Italy;(5)University of Pavia, Department of medical sciences- Gastroenterology unit, Santena, Italy;(6)Dipartmento di Medicina- Ospedale Sant’Eugenio, UO Nutrizione Clinica e Artificiale RM2, Roma, Italy;Italian Society of Artificial Nutrition and Metabolism (SINPE).
P455: Aminosalicylates in Ulcerative Colitis: old but gold?ECCO'22Year: 2022
Authors: Sequeira, C.(1);Santos, I.(1);Coelho, M.(1);Teixeira, C.(1);Mangualde, J.(1);Cremers, I.(1);Oliveira, A.(1);
(1)Centro Hospitalar de Setúbal- Hospital de São Bernardo, Gastroenterology, Setubal, Portugal;
P456: Risk of malignant tumors in patients with autoimmune diseases on ustekinumab therapy: a systematic review and meta-analysisECCO'22Year: 2022
Authors: Huang, K.(1,2);Zhang, Y.(1,2);Yao, L.(1,2);Zhang, Z.(1,2);Liu, R.(1,2);Cao, Q.(1,2);
(1)Sir Run Run Shaw Hospital- College of Medicine Zhejiang University, Department of Gastroenterology, Hangzhou, China;(2)Sir Run Run Shaw Hospital- College of Medicine Zhejiang University, Inflammatory bowel disease center, Hangzhou, China;
P457: Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s Disease and Ulcerative ColitisECCO'22Year: 2022
Authors: Danese, S.(1);Hanauer, S.B.(2);Jairath, V.(3,4);Mihaly, E.(5);Vicente Lidón, R.(6);Ott, E.(7);Gasink, C.(7);Miao, Y.(8);Ma, T.(8);Marano, C.(8);Sands, B.E.(9);
(1)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(2)Northwestern University, Feinberg School of Medicine, Chicago, United States;(3)University Hospital, Division of Gastroenterology- Department of Medicine, London, Canada;(4)Western University, Division of Epidemiology and Biostatistics, London, Canada;(5)Semmelweis University, Department of Internal Medicine, Budapest, Hungary;(6)Hospital Universitario Miguel Servet, Inflammatory Bowel Disease Unit, Zaragoza, Spain;(7)Janssen Scientific Affairs- LLC, Immunology, Horsham, United States;(8)Janssen Research & Development- LLC, Immunology, Spring House, United States;(9)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;
P458: Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn's disease (the SPEED-UP study) - A multi-center study from the paediatric IBD Porto group of ESPGHANECCO'22Year: 2022
Authors: Yerushalmy-Feler, A.(1);Pujol-Muncunill, G.(2);Martin-de-Carpi, J.(2);Kolho, K.L.(3);Levine, A.(4);Olbjørn, C.(5);Granot, M.(6);Bramuzzo, M.(7);Jonsson Rolandsdotter8, H.(8);Mouratidou, N.(9);Hradsky, O.(10);Scarallo, L.(11);Matar, M.(12);Magen Rimon, R.(13);Rinawi, F.(14);Shalem, T.(15);Najajra, H.(16);de Meij, T.(17);Aloi, M.(18);Velasco Rodríguez-Belvís, M.(19);Alvisi, P.(20);Schneider, A.M.(21);van Rheenen, P.(22);Navas-López, V.M.(23);Kiparissi, F.(24);Barrio, J.(25);Turner, D.(26);Cohen, S.(1);
(1)@Dana-Dwek@ Children's Hospital- Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine- Tel Aviv University, Pediatric Gastroenterology Institute, Tel Aviv, Israel;(2)Hospital Sant Joan de Déu, Department of Pediatric Gastroenterology- Hepatology and Nutrition, Barcelona, Spain;(3)Children's Hospital and University of Helsinki- Helsinki- Finland and Tampere University, Department of Paediatric Gastroenterology, Tampere, Finland;(4)Wolfson Medical Center and the Sackler Faculty of Medicine- Tel Aviv University, Pediatric Gastroenterology Unit- PIBD research center, Tel Aviv, Israel;(5)Akershus University Hospital, Department of Paediatric and Adolescent Medicine, Lørenskog, Norway;(6)Edmond and Lily Safra Children's Hospital- Sheba Medical Center, Pediatric Gastroenterology Unit, Ramat Gan, Israel;(7)Institute for Maternal and Child Health-IRCCS @Burlo Garofolo@, Gastroenterology- Digestive Endoscopy and Nutrition Unit, Trieste, Italy;(8)Department of Clinical Science and Education- Karolinska Institutet, Department of Gastroenterology- Sachs' Children and Youth Hospital, Stockholm, Sweden;(9)Karolinska University Hospital, Department of Pediatric Gastroenterology- Hepatology and Nutrition, Stockholm, Sweden;(10)Charles University in Prague and Motol University Hospital, Department of Pediatrics- 2nd Faculty of Medicine, Prague, Czech Republic;(11)Meyer Children's Hospital- 50139, Gastroenterology and Nutrition Unit, Florence, Italy;(12)Schneider Children's Medical Center and the Sackler Faculty of Medicine- Tel Aviv University, Institute of Gastroenterology- Nutrition and Liver Diseases-, Tel Aviv, Israel;(13)Ruth Children's Hospital of Haifa- Rambam Medical Center- Faculty of Medicine- Technion, Pediatric Gastroenterology and Nutrition Institute, Haifa, Israel;(14)Ha'Emek Medical Centre, Paediatrics Gastroenterology Unit, Afula, Israel;(15)Shamir Medical Center, The Jecheskiel Sigi Gonczarowski Pediatric Gastroenterology Unit, Zerifin, Israel;(16)Shaare Zedek Medical Center-, The Juliet Keiden Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(17)Amsterdam University Medical Centre, Department of Pediatric Gastroenterology, Amsterdam, Netherlands Antilles;(18)Umberto I Hospital- Sapienza University of Rome, Department of Maternal and Child Health- Pediatric Gastroenterology and Liver Unit-, Rome, Italy;(19)Hospital Niño Jesús, Paediatric Gastroenterology- Hepatology and Nutrition, Madrid, Spain;(20)Maggiore Hospital, Pediatric Gastroenterology Unit- Department of Pediatrics, Bologna, Italy;(21)Paracelsus Medical University, Department of Pediatrics, Salzburg, Austria;(22)University Medical Centre Groningen Beatrix Childrens Hospital, Paediatric Gastroenterology, Groningen, Netherlands Antilles;(23)Hospital Regional Universitario de Málaga, Pediatric Gastroenterology and Nutrition Unit, Málaga, Spain;(24)Great Ormond Street Hospital for Children NHS Foundation Trust- Great Ormond Street, Department of Pediatric Gastroenterology, London, United Kingdom;(25)Hospital Universitario de Fuenlabrada, Department of Paediatrics, Madrid, Spain;(26)Shaare Zedek Medical Center and the Hebrew University of Jerusalem, The Juliet Keiden Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;
P459: High inadequate surveillance rates in colitis-associated advanced neoplasia: a multicenter retrospective cohort studyECCO'22Year: 2022
Authors: Te Groen , M.(1);Derks , M.E.(1);Peters , C.P.(2);Dijkstra , G.(3);De Vries , A.C.(4);Römkens , T.E.(5);Horjus , C.S.(6);De Boer , N.K.(7);De Jong , M.E.(1);Nagtegaal , I.D.(8);Derikx , L.A.(1);Hoentjen , F.(1,9);
(1)Radboud University Medical Center, Inflammatory Bowel Disease Center- Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(2)Amsterdam University Medical Centers- location AMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(3)Groningen University Medical Center, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;(4)Erasmus Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(5)Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, Den Bosch, The Netherlands;(6)Rijnstate Hospital, Department of Gastroenterology and Hepatology, Arnhem, The Netherlands;(7)Amsterdam University Medical Centers- location VUmc, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(8)Radboud University Medical Center, Department of Pathology, Nijmegen, The Netherlands;(9)University of Alberta, Division of Gastroenterology- Department of Medicine, Edmonton, Canada;on behalf of the Dutch Initiative on Crohn’s and Colitis (ICC).
P460: A Real-World Picture of Adverse Drug Reactions in Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: Lemos Garcia, J.(1);Rosa, I.(2);Saraiva, S.(2);Moleiro, J.(2);Claro, I.(2);
(1)Instituto Português de Oncologia de Lisboa Francisco Gentil, Gastroenterology, Lisbon, Portugal;(2)Instituto Português de Oncologia de Lisboa: Instituto Portugues de Oncologia de Lisboa Francisco Gentil EPE, Gastroenterology, Lisbon, Portugal;
P461: COVID-19 outcomes in patients receiving anti-TNF treatments: A systematic review and meta-analysisECCO'22Year: 2022
Authors: Kokkotis, G.(1);Kitsou, K.(2);Xynogalas, I.(3);Spoulou, V.(2);Magiorkinis, G.(4);Poulakou, G.(3);Syrigos, K.(3);Bamias, G.(1);
(1)3rd Department of Internal Medicine- National and Kapodistrian University of Athens- Sotiria Hospital, GI Unit, Athens, Greece;(2)First Department of Paediatrics- National and Kapodistrian University of Athens, Immunobiology and Vaccinology Research Lab IVRL, Athens, Greece;(3)National and Kapodistrian University of Athens- Sotiria Hospital, 3rd Department of Internal Medicine, Athens, Greece;(4)National and Kapodistrian University of Athens- School of Medicine, Department of Hygiene- Epidemiology and Medical Statistics, Athens, Greece;
P462: Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of responseECCO'22Year: 2022
Authors: Srinivasan, A.(1,2,3);De Cruz, P.(3,4);Sam, M.(5,6,7);Toong, C.(5,6,7,8);van Langenberg, D.(1,2);
(1)Eastern Health, Department of Gastroenterology, Melbourne, Australia;(2)Monash University, Eastern Health Clinical School, Melbourne, Australia;(3)Austin Health, Department of Gastroenterology, Melbourne, Australia;(4)University of Melbourne, Austin Academic Centre, Melbourne, Australia;(5)NSW Health Pathology Liverpool Hospital, Department of Immunopathology, Sydney, Australia;(6)Ingham Institute of Applied Sciences, Immunology Research Group, Sydney, Australia;(7)University of NSW, South Western Sydney Clinical School, Sydney, Australia;(8)Liverpool Hospital, Department of Immunology, Sydney, Australia;
P463: Serum and mucosal Serpin E1 concentration correlates with endoscopic activity in inflammatory bowel disease - potential new activity markerECCO'22Year: 2022
Authors: Jójárt, B.(1);Molnár, T.(2);Kata, D.(3);Szabó, V.(1);Varga, Á.(1);Resál, T.(4);Bacsúr, P.(4);Szántó, K.(4);Földesi, I.(3);Molnár, T.(4);Maléth, J.(1);Farkas, K.(4);
(1)University of Szeged, Szent-Györgyi Albert Medical School- Department of Medicine- Szeged- Hungary- HAS-USz Momentum Epithelial Cell Signaling and Secretion Research Group- Szeged- Hungary- HCEMM-USz Molecular Gastroenterology Research Group- Szeged- Hungary, Szeged, Hungary;(2)University of Szeged, Szent-Györgyi Albert Medical School- Department of Medicine- Szeged- Hungary- HAS-USz Momentum Epithelial Cell Signaling and Secretion Research Group- Szeged- Hungary, Szeged, Hungary;(3)University of Szeged, Szent-Györgyi Albert Medical School- Institute of Laboratory Medicine- Szeged- Hungary, Szeged, Hungary;(4)University of Szeged, Szent-Györgyi Albert Medical School- Department of Medicine- Szeged- Hungary, Szeged, Hungary;University of Szeged Szent-Györgyi Albert Medical School Department of Medicine HAS-USz Momentum Epithelial Cell Signaling and Secretion Research Group
P464: Rac1/pSTAT3 expression in T lymphocytes: A potential pharmacodynamic marker for thiopurines in the treatment of Inflammatory Bowel Disease patients?ECCO'22Year: 2022
Authors: DebenMSc, D.(1);Creemers, R.(2,3);Van Adrichem, A.(4);Drent, R.(5);Merry, A.(6);Leers, M.(5);Van Bodegraven, A.(2,7);Wong, D.(1);
(1)Zuyderland MC, Dept. of Clinical Pharmacy- Clinical pharmacology and Toxicology, Sittard-Geleen, The Netherlands;(2)Zuyderland MC, Dept. of Gastroenterology- Geriatrics- Internal and Intensive Care Medicine Co-MIK, Sittard-Geleen, The Netherlands;(3)Maastricht University Medical Center, Dev. of Gastroenterology and Hepatology, Maastricht, The Netherlands;(4)Bravis MC, Dept. of Clinical Chemistry and Haematology, Roosendaal, The Netherlands;(5)Zuyderland MC, Dept. Of Clinical Chemistry and Haematology, Sittard-Geleen, The Netherlands;(6)Zuyderland MC, Zuyderland Academy, Sittard-Geleen, The Netherlands;(7)Amsterdam University Medical Center, Dept. of Gastroenterology and Hepatology, Amsterdam, The Netherlands;
P465: Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?ECCO'22Year: 2022
Authors: Fumery, M.(1);Nancey, S.(2);Filippi, J.(3);Altwegg, R.(4);Hebuterne, X.(3);Boschetti, G.(2);Veyrard , P.(5);Yzet, C.(1);Paul, S.(6);Roblin, X.(5);
(1)Amiens University Hospital, Gastroenterology, Amiens Cedex 1, France;(2)Lyon University Hospital, Gastroenterology, Lyon, France;(3)Nice University Hospital, Gastroenterology, Nice, France;(4)Montpellier University Hospital, Gastroenterology, Montpellier, France;(5)Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France;(6)Saint Etienne University Hospital, Immunology, Saint Etienne, France;GOLILOR Study group
